<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03223831</url>
  </required_header>
  <id_info>
    <org_study_id>CRE2016.701-T</org_study_id>
    <nct_id>NCT03223831</nct_id>
  </id_info>
  <brief_title>Partially Covered Versus Uncovered Pyloro-duodenal Stents for Unresectable Malignant Gastric Outlet Obstruction. A Double Blinded Randomised Controlled Trial.</brief_title>
  <official_title>Partially Covered Versus Uncovered Pyloro-duodenal Stents for Unresectable Malignant Gastric Outlet Obstruction. A Double Blinded Randomised Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National University Hospital, Singapore</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Singapore General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Changi General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baldota Institute of Digestive Diseases, Mumbai, India.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the efficacy of a novel partially covered (PC) versus uncovered (UC)&#xD;
      pyloro-duodenal stents (DS) in unresectable malignant gastric outlet obstruction. We&#xD;
      hypothesize that the use of PCDS could reduce the re-intervention rates when compared to&#xD;
      UCDS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This would be a prospective multi-centred double-blinded randomised controlled study&#xD;
      including all patients suffering from malignant gastric outlet obstruction due unresectable&#xD;
      primary gastro-duodenal or pancreatico-biliary malignancies. Five international institutions&#xD;
      in Hong Kong, Singapore and India would participate in the study.&#xD;
&#xD;
      The procedure would be performed under conscious sedation or monitored anaesthesia. The&#xD;
      patients would be randomised PCDS or UCDS after cannulation of the obstruction site is&#xD;
      achieved with the guide-wire. The patients or assessors would be blinded to the type of stent&#xD;
      that is inserted.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Actual">November 1, 2020</completion_date>
  <primary_completion_date type="Actual">November 1, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Recruited patients would be randomized to receive either uncovered duodenal stents or partially covered duodenal stents.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Recruited patients would not be informed of the type of stent that was inserted</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Re-intervention rate</measure>
    <time_frame>1 year</time_frame>
    <description>Percentage of patients requiring additional endoscopic intervention due to stent dysfunction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Technical success</measure>
    <time_frame>1 day</time_frame>
    <description>Successful placement of the DS across the site of obstruction, as confirmed by endoscopy or flouroscopy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical success</measure>
    <time_frame>3 days</time_frame>
    <description>Improvement of at least 1 point in the GOOS within 3 days after stent insertion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events rate</measure>
    <time_frame>1 year</time_frame>
    <description>Graded according to the lexicon of endoscopic adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 days</time_frame>
    <description>Death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastric outlet obstruction scores (GOOS)</measure>
    <time_frame>1 year</time_frame>
    <description>Scoring system for food intake</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent dysfunction</measure>
    <time_frame>1 year</time_frame>
    <description>Restenosis of the stent due to tumour ingrowth or overgrowth, stent migration, or fracture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of stent patency</measure>
    <time_frame>1 year</time_frame>
    <description>calculated from the time of stent placement to the time of stent dysfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment scores</measure>
    <time_frame>1 year</time_frame>
    <description>EORTC QLQ-C30</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Unresectable Malignant Gastric Outlet Obstruction</condition>
  <arm_group>
    <arm_group_label>Partially covered duodenal stent (PCDS)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The PCDS used in the current study is a partially covered metallic pyloro-duodenal stent. It consists of two portions. The stent is 2cm in diameter and the proximal 2cm of the stent is uncovered and flared. The remaining of the stent is covered, where a polytetrafluoroethylene (PTFE) membrane is held between two nitinol mesh.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Uncovered duodenal stent (UDS)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The UCDS used in the current study is an uncovered stent made of nitinol wire, with a diameter of 20mm. This stent is an unfixed-cell braided stent with low axial force, high flexibility and good conformability.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Partially covered pyloro-duodenal stent</intervention_name>
    <description>The PCDS (Niti-S COMVITM - Flare, Taewoong, Gyeonggi-do, South Korea) used in the current study is a partially covered metallic pyloro-duodenal stent. It consists of two portions (Figure 1). The stent is 2cm in diameter and the proximal 2cm of the stent is uncovered and flared. This is designed to provide anchorage of the stent to surrounding tissue and reduce the risk of migration. The remaining of the stent is covered, where a polytetrafluoroethylene (PTFE) membrane is held between two nitinol mesh to prevent the risk of tumour ingrowth into the stent. The stents come in lengths of 6, 8, 10 &amp; 12cm.</description>
    <arm_group_label>Partially covered duodenal stent (PCDS)</arm_group_label>
    <other_name>PCDS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Uncovered pyloro-duodenal stents</intervention_name>
    <description>The UCDS (Niti-S pyloric-duodenal D stent, Taewoong, Gyeonggi-do, South Korea) used in the current study is an uncovered stent made of nitinol wire, with a diameter of 20mm and length of 6,8,10,12cm. This stent is an unfixed-cell braided stent with low axial force, high flexibility and good conformability.</description>
    <arm_group_label>Uncovered duodenal stent (UDS)</arm_group_label>
    <other_name>UCDS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Consecutive patients ≥ 18 years old&#xD;
&#xD;
          -  Confirmed unresectable gastro-duodenal or pancreatico-biliary malignancies&#xD;
&#xD;
          -  Suffering from gastric outlet obstruction with a gastric outlet obstruction score of ≤&#xD;
             1 (appendix 1) 19&#xD;
&#xD;
          -  Performance status ECOG ≤3 (appendix 2)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior metallic stent placement&#xD;
&#xD;
          -  Severe comorbidities precluding the endoscopic procedure (such as cardiopulmonary&#xD;
             disease, sepsis, or a bleeding disorder)&#xD;
&#xD;
          -  Life expectancy of less than 1 month&#xD;
&#xD;
          -  History of gastric surgery&#xD;
&#xD;
          -  Linitus plastica&#xD;
&#xD;
          -  Coagulation disorders&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Unable to give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony Teoh, FRCSEd(Gen</last_name>
    <role>Principal Investigator</role>
    <affiliation>anthoyteoh@surgery.cuhk.edu.hk</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chinese University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <state>Hong Kong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>July 14, 2017</study_first_submitted>
  <study_first_submitted_qc>July 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2017</study_first_posted>
  <last_update_submitted>November 9, 2020</last_update_submitted>
  <last_update_submitted_qc>November 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Anthony Teoh</investigator_full_name>
    <investigator_title>Honorary Associate Professor</investigator_title>
  </responsible_party>
  <keyword>unresectable malignant gastric outlet obstruction</keyword>
  <keyword>Partially covered pyloro-duodenal stents</keyword>
  <keyword>uncovered pyloro-duodenal stents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastric Outlet Obstruction</mesh_term>
    <mesh_term>Pyloric Stenosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

